Drug development, together with associated trials, are mainly undertaken with white Caucasians in mind. As a result, drugs often work differently depending on ethnicity. Today we know that ~99% of the population has a known significant mutation that affects at least one medication. Drug development has relied on sweeping assumptions - the idea of the average patient who will respond in a particular way. This one size fits all model is no longer accepted, and health and insurance providers need to be able to demonstrate that their business model is non-discriminatory and moving towards personalised medicine to aim for the best outcome for patient and society.
Enquire nowQuote from Ravi Sharma, Director for England at the Royal Pharmaceutical Society:
"We do not have the clinical decision support tool for clinicians to be able to prescribe and not all clinicians know how to tailor particular medicines according to people's genomic responses."
email info@signigene.com